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Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE) is a rare autosomal 
recessive disease caused by TYMP mutations and thymidine phosphorylase (TP) deficiency. 
Thymidine and deoxyuridine accumulate impairing the mitochondrial DNA maintenance and 
integrity. Clinically, patients show severe and progressive gastrointestinal and neurological 
manifestations. The onset typically occurs in the second decade of life and mean age at death 
is 37 years. Signs and symptoms of MNGIE are heterogeneous and confirmatory diagnostic 
tests are not routinely performed by most laboratories, accounting for common misdiagnosis. 
Factors predictive of progression and appropriate tests for monitoring are still undefined. 
Several treatment options showed promising results in restoring the biochemical imbalance of 
MNGIE. The lack of controlled studies with appropriate follow-up accounts for the limited 
evidence informing diagnostic and therapeutic choices. The International Consensus 
Conference (ICC) on MNGIE, held in Bologna, Italy, on March 30th-31st, 2019, aimed at an 
evidence-based consensus on diagnosis, prognosis and treatment of MNGIE among experts, 
patients, caregivers and other stakeholders involved in caring the condition. The conference 
was conducted according to the National Institute of Health Consensus Conference 
methodology. A consensus development panel formulated a set of statements and proposed a 
research agenda. Specifically, the ICC produced recommendations on: (1) diagnostic 
pathway; (2) prognosis and the main predictors of disease progression; (3) efficacy and safety 
of treatments; and (4) research priorities on diagnosis, prognosis and treatment. The Bologna 
ICC on diagnosis, management and treatment of MNGIE provided evidence-based guidance 
for clinicians incorporating patients’ values and preferences. 






This is the first International Consensus Conference (ICC) aimed at an evidence-based 
consensus on diagnosis, prognosis and treatment among experts, patients, caregivers and 
other stakeholders involved in MNGIE. The ICC provided recommendations on diagnostic 
pathway, prognosis and the main predictors of disease progression, efficacy and safety of 
treatments, and, finally, identified priorities on cogent research topics on MNGIE.  
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Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE) is an autosomal 
recessive disease caused by mutations in the thymidine phosphorylase gene (TYMP)(Pacitti et 
al 2018). TYMP encodes for thymidine phosphorylase (TP), which catabolizes thymidine 
(dThd) and deoxyuridine (dUrd) into their respective bases. TYMP mutations markedly 
reduce/abolish TP activity leading to accumulation of dThd and dUrd and mitochondrial 
DNA (mtDNA) defects.MNGIE is an ultra-rare condition, characterized by severe 
gastrointestinal (GI) and neurological symptoms(D'Angelo et al 2016) that is often 
misdiagnosed. Although the disease is progressive and fatal, natural history is still 
uncharacterized(Nishino et al 2000; Garone et al 2011; Corazza et al 2019). Various 
experimental therapeutic approaches aimed to the temporary enzyme replacement, e.g. 
erythrocyte encapsulated TP (EE-TP) infusions (Pacitti et al 2018), or permanent restoration 
of TP activity through hematopoietic stem cell transplantation (HSCT) (Halter et al 2015) and 
orthotopic liver transplantation (OLT) (De Giorgio et al 2016). Since the severity of GI 
symptoms influences treatment success, timing of HSCT and OLT is crucial (Halter et al 
2015; De Giorgio et al 2016). Possible future options include gene therapy, which has shown 
pre-clinical efficacy (Torres-Torronteras et al 2014; Cabrera-Pérez et al 2015; Torres-
Torronteras et al 2016; Torres-Torronteras et al 2018; Yadak et al 2018; Cabrera-Pérez et al 
2019). 
An International Consensus Conference (ICC) was held to produce an unbiased, evidence-
based assessment on MNGIE, leading to a consensus and guidance on the following areas: (I) 
diagnostic pathway; (II) prognosis and main predictors of disease progression; (III) efficacy 




and safety of treatments. 
 
2 METHOD 
2.1 Panel/experts selection 
The Bologna MNGIE ICC was organized and promoted by the Azienda Ospedaliero-
Universitaria di Bologna, Policlinico S.Orsola-Malpighi, and the IRCCS Istituto delle 
Scienze Neurologiche di Bologna, Italy, according to the NIH Consensus Development 
Program methodology(Nair et al 2011) and the Methodological Handbook of the Italian 
National Guideline System(Candiani et al 2009). The members of the technical committee 
(TC) and scientific committee (SC), the expert workgroups (EWGs) and the consensus 
development panel (CDP) were invited based on their expertise in the field, ensuring the 
participation of all the clinical and non-clinical stakeholders (including patients) and a broad 
involvement of healthcare professionals from all the clinical aspects of MNGIE. Researchers 
were identified based on a review of the main authors in the field. The official language of 
the conference was English supported by a professional translator. A declaration of interest 
form was signed by every participant. Of the 36 stakeholders invited to the ICC, four 
declined and five accepted but did not participate. One member attended via teleconference. 
 
2.2 The assignment, scoping and assessment stages  
The assignment, scoping and assessment stages occurred between January 2018 and March 
2019. The ICC took place in Bologna on March 30th and 31st. During assignment, the SC 
appointed a TC, a CDP and three EWGs (Appendix 1). The SC identified three MNGIE 




topics (diagnosis, prognosis and treatment) and questions to be addressed by the EWGs 
(scoping). Assessment of the evidence was carried out by the TC through a systematic 
literature search with evidence mapping (Bragge et al 2011) according to the PRISMA 
guidelines (Moher et al 2009) (Appendix 2). Studies of any design, in English language, 
published in full on peer reviewed journals, reporting original data on diagnosis, prognosis, 
and/or treatment of MNGIE on humans were searched on MEDLINE and the Cochrane 
Central Register of Controlled Trials in January 2018 and 2019, and finally updated in May 
2020. Retrieved studies were selected independently by LV, EB and RD. Disagreement was 
resolved by discussion. Each study was graded according to four classes of methodological 
quality (from Class I, highest quality to Class IV, lowest quality) according to the 
Classification of Evidence Schemes of the Clinical Practice Guideline Process Manual of the 
American Academy of Neurology (Appendix 3) (Gronseth et al 2011) and appraised by the 
EWGs to draft answers to the questions posed by the SC. During the ICC the scientific 
evidence and the answers to the questions were presented by the EWGs. The final statements 




The literature search retrieved 1,305 citations after duplicate removal; 1,146 were excluded 
because the covered topic was not of interest for our review (Appendix 2). Of the 159 full 
text articles selected, 81 were excluded mostly because they were animal studies or studies 
describing genetic mutations causing the clinical manifestations of MNGIE. The 78 selected 




articles were submitted to the three working groups. Since 36 of them were out of scope 
regarding the specific topics, 42 were used for the statements (4 of them were assigned to two 
topics each). The CDP issued the following Position Statements on diagnosis, prognosis and 
treatment of MNGIE. In Appendix 4 a summary of the scientific evidence and rationale for 
the statements is presented. 
 
3.1 Position Statements on the Diagnosis of MNGIE 
The following statements are based on 7 Class III level studies (case series with controls) 
(Spinazzola et al 2002; Nishigaki et al 2003; Marti et al 2004; Valentino et al 2007; 
Mohamed et al 2014; Gramegna et al 2018; Kipper et al 2020), 7 Class IV level studies (two 
case series and five case reports) (Millar et al 2004; Marti et al 2005; Giordano et al 2006; 
Filosto et al 2011; Garone et al 2011; Scarpelli et al 2013; Corazza et al 2019) and expert 
opinion. 
3.1.1 Clinical elements that can indicate MNGIE 
MNGIE can be suspected when one or more of the following clinical cardinal elements are 
present: 
• Symptoms and signs of otherwise unexplained GI dysmotility 
• Thin constitution/cachexia, even with normal food behaviour and nutritional intake  
• Neurological features such as ptosis and symptoms suggesting peripheral neuropathy 
• A progressive course of the above with frequent misdiagnosis 
The features of the full-blown MNGIE typically are: 




• Symptoms onset: childhood, adolescence/young adulthood (typical), adulthood (late 
onset, >40 years) 
• GI symptoms/signs:  sub-occlusive episodes, nausea, vomiting, early satiety, 
borborygmi, severe abdominal pain, abdominal distension, dysphagia, constipation and 
diarrhoea, acute peritonitis due to small bowel perforation 
• Unexplained weight loss, thinness, cachexia, even with normal food behaviour and 
nutritional intake 
• Radiological GI signs: small bowel diverticulosis, GI dilation (e.g. gastric or intestinal 
dilation) 
• Neurological symptoms/signs: chronic progressive external ophthalmoplegia (CPEO), 
ptosis, peripheral neuropathy, hearing loss 
• Neuroradiological signs: leukoencephalopathy without other neuroradiological 
abnormalities 
• Metabolic alterations: liver steatosis evolving in cirrhosis, pancreatitis, early onset 
diabetes mellitus, increased triglyceride levels, elevated plasma lactate 
MNGIE is most frequently misdiagnosed as: 
• Anorexia nervosa 
• GI diseases: Crohn’s disease, coeliac disease, esophagitis and/or gastritis, irritable bowel 
syndrome, superior mesenteric artery syndrome, Whipple’s disease, chronic intestinal 
pseudo-obstruction 




• Neurological diseases: chronic inflammatory demyelinating polyneuropathy, Charcot-
Marie-Tooth disease, other mitochondrial diseases such as CPEO, Kearns-Sayre 
syndrome 
3.1.2 Recommended diagnostic testsCardinal diagnostic tests:  
• Swallowing test, gastric emptying and GI manometry (when possible): altered GI 
motility and transit 
• Brain MRI: leukoencephalopathy without any other neuroradiological abnormalities 
(almost universally present) (Table 1 and Fig. 2) 
• Nerve conduction studies: peripheral neuropathy, predominantly demyelinating 
Ancillary tests: 
• Muscle biopsy: ragged-red and COX deficient fibers, deficiencies of respiratory chain 
enzyme activities, ultrastructurally abnormal mitochondria, and mtDNA depletion, 
multiple deletions, and somatic point mutations 
• Mucosal GI histology of small bowel (to exclude other conditions), and gut full thickness 
biopsy (when possible) 
 
3.1.3 Recommended metabolic and genetic tests 
Mandatory tests to confirm MNGIE diagnosis: 
• TYMP sequencing: homozygous or compound heterozygous allelic pathogenic variants, 
no further testing. 
• If one variant of uncertain significance or a wild-type sequence is identified, the 
following biochemical assessments should be performed: 




o TP activity: severely reduced or virtually absent in the buffy coat (below 8% 
of the mean of reference TP values; laboratory cutoffs may differ depending 
on sample processing and biochemical assay). If TP activity is only partially 
reduced, then it is mandatory to measure plasma dThd and dUrd levels. The 
diagnosis is excluded if TP activity is normal. 
o dThd and dUrd levels: increased in plasma (assessment of urine is unreliable) 
Fig. 1 shows the recommended algorithm in persons with suspected MNGIE. 
 
3.2 Position Statements on the Prognosis of MNGIE 
The following statements are based on one Class II level study (retrospective cohort) (Garone 
et al 2011), two Class III level study (retrospective cohorts) (Nishino et al 2000; Corazza et al 
2019), 4 Class IV level studies (four case reports) (Ionasescu et al 1984; Carrozzo et al 1998; 
Marti et al 2005; Massa et al 2009) and expert opinion. 
 
3.2.1 The natural history of MNGIE  
• Mean age at onset: 17.9 years (5 months - 43 years). 
• GI symptoms (57% at onset; 100% at diagnosis); onset/diagnosis: diarrhea, abdominal 
pain, borborygmi, vomiting, pseudo-obstruction (32%- 65%), weight loss/cachexia 
(100%); evolution: diverticulosis/diverticulitis (67%), hepatopathy (22%). 
• Neurological symptoms / signs (43% at onset; 100% at diagnosis); 
onset/diagnosis/evolution: ocular signs (ptosis, ophthalmoparesis) (74-100%), 




polyneuropathy (92-100%), hearing loss (39-45%), leucoencephalopathy (±100%); 
cognitive impairment (20%). 
• Symptoms are cumulative and progressive. 
• Mean age at death is reported to range between 35 and 37 years; survival 100% before 19 
years and < 5% after 50 years. 
• Death is mainly due to GI and liver complications (intestinal perforation, intestinal 
bleeding, liver failure, aspiration pneumonia, complications due to small intestinal 
bacterial overgrowth (SIBO) or infection related to central venous catheter for parenteral 
nutrition) and cachexia. 
 
Overall survival is the only outcome reported in the literature. Weight loss is an important 
feature of MNGIE, but data on its prognostic role are lacking. 
 
3.2.2 Phenotypes of MNGIE 
MNGIE has two different presentations distinguished by age of onset: “Early Onset” (or 
“Classic”) and “Late Onset” (Table 2). Severity can vary among family members. Available 
data do not allow a differentiation of clinical phenotypes based on symptoms at onset (GI or 
neurological). Neurological manifestations may be subtle and insidious leading to late 
recognition by both patients and physicians. When GI symptoms are the first manifestation, 
the diagnosis and consequently the appropriate treatment may be significantly delayed 
because of misdiagnosis. 




In clinical practice, the presence and/or severity of GI involvement are considered a negative 
prognostic factor, for both morbidity and mortality. Apparently, there is no correlation 
between genotype, phenotype and outcome. Residual TP activity of 10-15% has been 
associated with moderate increases of nucleosides and “Late Onset” MNGIE compared to the 
“Classic” form. 
 
3.2.3 Impact of different phenotypes on the natural history of MNGIE and outcomes 
Whether “Classic” (“Early Onset”) and “Late Onset” phenotypes have different disease 
progression remain unsettled. All patients with Late Onset phenotype reported in the 
literature were alive at follow-up ranging between 8 to 24 years. In the “Classic” phenotype, 
age of onset is not related to life expectancy. At present, overall survival after onset is the 
only available outcome reported in the literature. 
 
3.2.4 Events indicating disease progression 
The following events can be considered as important milestones related to progression: GI 
sub-occlusive episode, decompressive percutaneous endoscopic gastrostomy (PEG), 
aspiration pneumonia, abdominal surgical procedures, septic episode due to SIBO, need for 
enteral tube feeding or PEG, onset of intestinal failure (and subsequent need of parenteral 
nutrition), liver cirrhosis, loss of unaided walking ability. Recommended assessments to 
monitor MNGIE progression are listed in Table 3. 
 
3.3 Position Statements on the Treatment of MNGIE 




The following statements are based on 25 Class IV level studies (one retrospective cohort, 
one case series, 24 case reports) (Hirano et al 2006; la Marca et al 2006; Lara et al 2006; 
Yavuz et al 2007; Moran et al 2008; Filosto et al 2012; Sicurelli et al 2012; Bax et al 2013; 
Finkenstedt et al 2013; Hussein 2013; Ariaudo et al 2015; Casarez et al 2015; Halter et al 
2015; Peedikayil et al 2015; De Giorgio et al 2016; Sivadasan et al 2016; Baker et al 2017; 
D'Angelo et al 2017; Roeben et al 2017; Chandra et al 2018; Hanbali et al 2018; Levene et al 
2018; Yadak et al 2018; Levene et al 2019; Kripps et al 2020) and expert opinion. 
 
3.3.1 Treatments effective in temporarily restoring the biochemical imbalance 
“Short term” is defined as a period of time required stabilizing a patient waiting for 
permanent treatment or as compassionate use. 
Overall, hemodialysis (HD), continuous ambulatory peritoneal dialysis (CAPD), EE-TP and 
platelet infusion have been effective in achieving temporary improvement of the biochemical 
imbalance in several MNGIE patients. However, there are practical limitations, safety issues 
and unclear clinical effects associated with these approaches.  
Specifically: 
• EE-TP seems to be effective on a monthly-based administration in terms of biochemical 
and clinical improvement (4 patients out of 5); mild immunological reaction against 
bacterial TP mainly with repeated infusions may occur (2 out of 5 patients). EE-TP is 
currently under clinical evaluation. 
• CAPD seems to be well tolerated with anecdotal biochemical efficacy; peritoneal 
sclerosis due to repeated procedures may be a safety concern.  




• HD has very short-term biochemical effects as nucleosides return to high levels a few 
hours after the procedure. Disadvantages include the need of venous access, an intensive 
procedure schedule (3-4 sessions per week) and the possible occurrence of hypotension, 
fluid overload or infections. 
• Platelet infusion has been reported to achieve some biochemical improvement. Safety 
issues include allergic and immunological reactions. 
 
We suggest consideration of EE-TP or CAPD in patients waiting for a permanent treatment 
option, or for compassionate use. 
 
3.3.2 Effective treatments that permanently restore the biochemical imbalance 
Permanent treatment options are aimed at restoring TP resulting in the long-term clearance of 
dUrd and dThd. The improved biochemical profile is expected to be associated with clinical 
stabilization (i.e., halting tissue damage progression) or improvement. 
• HSCT is effective in permanently restoring the biochemical imbalance. It requires 
chemotherapy and immunosuppressive therapy and is associated with a high risk for 
complications and mortality related to therapy, including graft versus host disease. 
• OLT is effective for permanent restoration of the biochemical imbalance and it does not 
require preoperative conditioning. Patients with severe malnutrition or previous episodes 
of small bowel perforation, sub-occlusion or sepsis related to SIBO could be at high risk 
of peri- and post-operative complications and should not be considered for OLT; 




metabolic complications such as chronic kidney insufficiency, diabetes or cardiovascular 
disease related to long-life immunosuppressive therapy may be long-term issues. 
 
3.3.3 Treatments that improve the patient’s health in terms of quality of life (QoL) and 
functional status 
Any temporary or permanent treatment should be considered as soon as diagnosis is 
confirmed. EE-TP and CAPD are effective with some temporary improvement of QoL and 
minimal complications. HSCT is effective in the long term for improving QoL and functional 
status, although limited by a high post-treatment mortality rate (63%) in severely 
symptomatic adult patients. OLT is effective in the long term for improving QoL and 
functional status, although limited evidence is available. 
 
3.3.4 Appropriateness of treatments that temporarily or permanently restore the 
biochemical imbalance 
Temporary treatments should be considered at any age based on clinical condition, before 
permanent treatments, e.g. while waiting /on list for either HSCT or OLT. Once the diagnosis 
is confirmed, permanent treatments are recommended as early as possible for both HSCT and 
OLT according to eligibility criteria (e.g. severity). Ideal candidates should be those at an 
early stage of MNGIE. In patients who are oligosymptomatic, either HSCT or OLT can be 
considered. HSCT should be considered in pediatric patients and young adults with normal 
liver function, mild or no GI manifestations (e.g. absence of intestinal pseudo-obstruction, 
peritonitis, pancreatitis) and in case of matched donors with normal genotype. A busulphan-




based myeloablative regimen as a preparation to HSCT is recommended. OLT would be the 
preferred permanent treatment option for patients with progressive liver involvement (i.e. 
fibrosis and/or abnormal liver function). Transplant from a living donor can be considered 
only if the donor’s TYMP genotype is normal. In fully informed patients who are severely 
affected by MNGIE and unlikely to survive permanent correction procedures, temporary 
metabolite restorative treatments (EE-TP and CAPD) should be offered and discussed. 
 
3.3.5 Assessments predicting the effect of treatment 
The following assessments may be predictive of effects of treatment: 
• Serial plasma levels of dThd and dUrd 
• Serial TP activity measurement in buffy coat (only for HSCT) 
The clinical outcome after treatment depends upon the patient’s disease status prior to 
treatment. Assessments evaluating the disease status at the time of diagnosis may indicate 
whether a proposed treatment is likely to be effective. The extent of hepatic, GI involvement 
and cachexia are key indicators of survival, therefore assessments evaluating these aspects 
may be predictive of treatment outcome. Several clinical outcome assessments may be used 




This is the first consensus statement on MNGIE, prompted by the severity of a condition that, 
although very rare, affects mainly young adults causing substantial reduction of life 




expectancy and QoL. Several potentially useful treatments can be offered to patients, and 
more may be soon available. It is important to coordinate the work of clinicians and 
researchers in order to generate new useful evidence and provide patients with reliable and 
consistent information about their condition. 
 
4.1 Main findings 
The ICC developed over two days. During the first day one representative of each of the three 
EWG presented (in a meeting open to the general audience) the results of a systematic search 
of the literature relative to the topic. Each representative summarized the scientific evidence 
and proposed conclusions. Presentations were followed by discussion, moderated by the chair 
of the Jury and by a methodologist, during which disagreements were resolved and tentative 
recommendations were drafted. No disagreement required formal voting. Multi-stakeholder 
involvement in the public discussion was ensured by involving patients’ advocacy 
organizations. 
 
4.2 Strengths and limitations 
MNGIE is genetically determined and gene therapies are still at a pre-clinical stage. 
Nevertheless, promising treatments that could potentially modify the course of the condition 
are emerging. The efficacy of available treatments is still not completely defined, and 
probably influenced by the stage of the disease. Due to the rarity of the condition, the 
evidence on MNGIE is limited to few case reports and small case series. The ICC aimed at 
reaching for the first time an evidence-based consensus involving researchers, patients and 




their families and healthcare providers on the clinical and instrumental hallmarks of MNGIE, 
its expected course and the main criteria guiding the choice of the most appropriate treatment 
in individual patients. Research priorities were also identified (Appendix 5) along with the 
newborn promoting collaboration and networks. 
Our process had several limitations. First, since the available evidence is scanty and of low 
quality, the provided guidance is mainly based on the opinion of experienced clinicians and 
researchers, and therefore subject to bias. Adopting a rigorous and explicit methodology and 
warranting the possibility of discussion in every stage of the process through public 
presentations compensated this limitation. In order to avoid a prevailing view by medical 
experts, we ensured a formal participation of a leading patient advocacy association among 
the stakeholders in the jury that formulated the guidance and prompted questions and 
comments by patients and their families in the audience during discussion. Personal interests, 
that could bias the point of view of individuals, were declared by each participant. Secondly, 
there was a partial overlapping in the composition of the scientific workgroups and the SC, 
since some of the members of the formers were also part of the latter. This could have been a 
potential source of bias that we mitigated by creating groups as large as possible, facilitating 
a plurality of views within different areas. Due to the rarity of MNGIE and its recent 
discovery, the number of knowledgeable researchers and clinicians was low. Although the 
conference was international and almost all invited persons accepted the invitation, the total 
number of participants did not allow a complete separation of roles. 
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Table 1 - Recommended brain MRI protocol. 
MRI technical requirements 
Brain MRI should be performed using a magnetic field of at least 1.5T with a slice 
thickness =3-5mm for 2D acquisition or < 3 mm for 3D reconstruction 
MRI protocol 
• Axial 2D T2 FLAIR/T2-weighted 
• Sagittal 2D T2-FLAIR/T2-weighted 
• 3D T2-FLAIR/T2-weighted in alternative to axial and sagittal T2-FLAIR/T2-
weighted 
• Axial DWI 
• Axial T2* or SWI 
• Axial 2D or 3D T1-weighted before and after contrast * 
• Single voxel proton MRS sequence in white matter with signal intensity changes ** 
Description of leucoencephalopathy (Fig. 2) 
White matter hyperintensity in T2-weighted imaging, usually bilateral, patchy and/or 
diffuse, periventricular and/or subcortical. It may be cloud-like in the early stage of the 
disease. 
White matter hyperintensity generally spares U fibers, does not have mass effect or 
contrast enhancement and must be mostly symmetrical. Its reversibility after therapy is 
still under debate. 
The involvement of corpus callosum, white matter capsules, basal ganglia, thalami, 




midbrain, pons, and cerebellar white matter in general has been observed in patients with 
long standing condition. 
* MNGIE patients show no post-contrast enhancement in contrast with some white matter disorders; 
** MNGIE patients show normal metabolite ratios: this is not the case for most brain white matter 
disorders(Oz et al 2014). Abbreviations: DWI, diffusion-weighted imaging; FLAIR, Fluid-attenuated 
Inversion Recovery; MRS, Magnetic Resonance Spectroscopy; SWI, Susceptibility-Weighted 
Imaging. 
 




Table 2 - Features of “Classic” and “Late Onset” phenotype of MNGIE. 
Classic phenotype (n=161)* Late Onset phenotype (n=8)* 
Age of onset<40 years old Age of onset ≥40 years old 
Leukocyte TP enzymatic activity: 0-10% 
Plasma levels: dThd>4 and/or dUrd>5 
µmol/L 
Leukocyte TP enzymatic activity: 10-30% 
 Plasma levels: dThd 0.05-4 and/or dUrd 
0.05-5µmol/L 
GI symptoms 100% GI symptoms 100% 
Leukoencephalopathy 100% Leukoencephalopathy 100% 
Polyneuropathy 92-100% Polyneuropathy 60% 
Ocular signs 74-100% Ocular signs 100% 
Hearing loss 39-45% Hearing loss 75% 
*Number of cases described at the time of the ICC. 




Table 3 - Recommended assessments to monitor MNGIE progression. 
Clinical/instrumental 
assessments of disease course 
Parameters Frequency of 
assessment 
(months) 
GI symptoms severity Abdominal pain (assessed with 
VAS), diarrhea, vomiting, oral 
intake (assessed with diary) 
3 
Metabolic assessment FGF21*, GDF15*, blood lactate 6 
Body weight and body 
composition trajectory 
BMI, prealbumin, albumin, CRP, 
BIA (bioimpedentiometry) 
3 
Polyneuropathy Electroneurography 12 
Hepatic function and imaging LFTs, PT, INR, liver function 
impairment (assessed with Child-




Quality of life (QoL) SF36 6 
Fatigue FSS or FIS 6 
Functional status Karnofsky/Lansky Performance 
Status Scale 
6 




Leukoencephalopathy Brain MRI (no contrast agent 
required) 
24 
Abbreviations: BIA, bioelectrical impedance analysis; BMI, body mass index; CRP, C-reactive 
protein; FGF, fibroblast growth factor 21; FSS, fatigue severity scale; FIS, fatigue impact scale; GDF, 
growth differentiation factor 15; GI, gastrointestinal; INR, international normalized ratio; LFTs, liver 
function tests; MRI, magnetic resonance imaging; PT, prothrombin time; SF, short form 36. VAS, 
visual analogue scale. 
* FGF21 and GDF15 are ancillary biomarkers of mitochondrial myopathy due to mtDNA 
maintenance defects recently established for their usefulness in documenting natural history of 
progression or improvements (after therapy) marking skeletal muscle in mitochondrial myopathies 
(Lehtonen JM, Forsström S, Bottani E, et al. FGF21 is a biomarker for mitochondrial translation and 
mtDNA maintenance disorders. Neurology 2016;87:2290-2299). 
 
FIGURE LEGEND 
Fig. 1 - Diagnostic algorithm in MNGIE. 
 
Fig. 2 - Brain MRI examination from a 27-year-old severely affected MNGIE male patient. 
A) Axial T2-FLAIR shows bilateral and symmetrical diffuse cerebral white matter 
hyperintensity, with relative sparing of subcortical U fibers and patchy bilateral 
hyperintesities in the basal ganglia, thalami and corpus callosum. B) Hyperintensities are also 
seen bilaterally in the pons and cerebellar white matter. (Courtesy of Prof Raffaele Lodi and 
Dr. Laura Ludovica Gramegna, IRCCS Istituto delle Scienze Neurologiche di Bologna). 
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